drugset
drugset / Trial / NCT06293300

Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)

NCT06293300 ↗

Phase 2 Recruiting 50 enrolled University of Miami United States Department of Defense · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research is to understand and treat Traumatic Brain Injury (TBI) associated photophobia (light sensitivity) and its impact on visual function.

Timeline

Start
2024-09-30
Primary completion
2026-09-30
Completion
2026-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 35 iu —

Indications

traumatic brain injury